These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Management of worsening multiple sclerosis with mitoxantrone: a review. Fox EJ Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460 [TBL] [Abstract][Full Text] [Related]
3. Secondary progressive multiple sclerosis: current knowledge and future challenges. Rovaris M; Confavreux C; Furlan R; Kappos L; Comi G; Filippi M Lancet Neurol; 2006 Apr; 5(4):343-54. PubMed ID: 16545751 [TBL] [Abstract][Full Text] [Related]
4. Natural history of multiple sclerosis: a unifying concept. Confavreux C; Vukusic S Brain; 2006 Mar; 129(Pt 3):606-16. PubMed ID: 16415308 [TBL] [Abstract][Full Text] [Related]
7. Impact of diagnosis and early treatment on the course of multiple sclerosis. Noyes K; Weinstock-Guttman B Am J Manag Care; 2013 Nov; 19(17 Suppl):s321-31. PubMed ID: 24494633 [TBL] [Abstract][Full Text] [Related]
8. [Update on current care guidelines: diagnostics, treatment and rehabilitation of multiple sclerosis]. Elovaara I; Atula S; Erälinna JP; Färkkilä M; Pirttilä T; Remes A; Ruutiainen J; Varis T; ; Duodecim; 2010; 126(2):199-200. PubMed ID: 20405605 [TBL] [Abstract][Full Text] [Related]
9. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies. Wingerchuk DM; Carter JL Mayo Clin Proc; 2014 Feb; 89(2):225-40. PubMed ID: 24485135 [TBL] [Abstract][Full Text] [Related]
10. [Mitoxantrone for the treatment of patients with multiple sclerosis]. Komori M; Kondo T; Tanaka M Brain Nerve; 2009 May; 61(5):575-80. PubMed ID: 19514518 [TBL] [Abstract][Full Text] [Related]
11. Management of multiple sclerosis: current trials and future options. Noseworthy JH Curr Opin Neurol; 2003 Jun; 16(3):289-97. PubMed ID: 12858064 [TBL] [Abstract][Full Text] [Related]
12. Diagnostic uncertainty during the transition to secondary progressive multiple sclerosis. Katz Sand I; Krieger S; Farrell C; Miller AE Mult Scler; 2014 Oct; 20(12):1654-7. PubMed ID: 24493475 [TBL] [Abstract][Full Text] [Related]
13. A focus on secondary progressive multiple sclerosis (SPMS): challenges in diagnosis and definition. Inojosa H; Proschmann U; Akgün K; Ziemssen T J Neurol; 2021 Apr; 268(4):1210-1221. PubMed ID: 31363847 [TBL] [Abstract][Full Text] [Related]
14. Treatment of multiple sclerosis. Anlar O CNS Neurol Disord Drug Targets; 2009 Jun; 8(3):167-74. PubMed ID: 19601814 [TBL] [Abstract][Full Text] [Related]
15. The Swiss Multiple Sclerosis Cohort-Study (SMSC): A Prospective Swiss Wide Investigation of Key Phases in Disease Evolution and New Treatment Options. Disanto G; Benkert P; Lorscheider J; Mueller S; Vehoff J; Zecca C; Ramseier S; Achtnichts L; Findling O; Nedeltchev K; Radue EW; Sprenger T; Stippich C; Derfuss T; Louvion JF; Kamm CP; Mattle HP; Lotter C; Du Pasquier R; Schluep M; Pot C; Lalive PH; Yaldizli Ö; Gobbi C; Kappos L; Kuhle J; PLoS One; 2016; 11(3):e0152347. PubMed ID: 27032105 [TBL] [Abstract][Full Text] [Related]
16. MRI as an outcome in multiple sclerosis clinical trials. Daumer M; Neuhaus A; Morrissey S; Hintzen R; Ebers GC Neurology; 2009 Feb; 72(8):705-11. PubMed ID: 19073945 [TBL] [Abstract][Full Text] [Related]